MedPath

Intraperitoneal injection of in vitro expanded Gamma Delta T cells together with zoledronate for the treatment of malignant ascites to ovarian cancer ; to evaluate the safety and efficacy. (A Phase 1/2a study)

Phase 1
Conditions
Ovarian cancer,tubal carcinoma, primary peritoneal cancer
Registration Number
JPRN-UMIN000015233
Lead Sponsor
Tokyo Women's Medical University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
7
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients who positive for anti-adult T-cell leukemia-associated antigen or anti-human immunodeficiency virus antibody,or hepatitis. 2)Patients who have uncontrolled infection 3)Patients receiving immunodepressant 4)Patient who were pregnant or lactating 5)Other patients judged to be ineligible by the attending investigators

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety of i.p. injection of autologous Gamma Delta T cells.
Secondary Outcome Measures
NameTimeMethod
Puncture-free-survival,QOL and immunological proof-of-concept of antitumor activity.
© Copyright 2025. All Rights Reserved by MedPath